Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

$Affimed NV (AFMD.US)$ 🤔 Affimed Announces Positive Results...

🤔
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Positive
High overall response rate of 86% in heavily pretreated patients
Complete response rate of 55% in patients with treatment options
Well-managed safety profile with no unexpected safety signals
Successful validation of treatment in multi-center setting

Negative
None.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
3
+0
Translate
Report
2244 Views
Comment
Sign in to post a comment